Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Open-Label Study of the Safety, Tolerability, Efficacy, and PK of ProMetic BioTherapeutics IGIV (Human) 10% in Adults and Children With Primary Immunodeficiency Diseases
Conditions
Interventions
Immune Globulin Intravenous
Prometic's Immune Globulin Intravenous 10%
Locations
13
United States
University of California, Irvine
Irvine, California, United States
Children's Hospital Los Angeles
Los Angeles, California, United States
Immunoe International Research
Centennial, Colorado, United States
National Jewish Hospital
Denver, Colorado, United States
Allergy Associates of the Palm Beaches
North Palm Beach, Florida, United States
Johns Hopkins All Children's Hospital
St. Petersburg, Florida, United States
Start Date
January 26, 2016
Primary Completion Date
January 11, 2019
Completion Date
January 11, 2019
Last Updated
November 5, 2021
NCT03394053
NCT04902807
NCT05755035
NCT03330795
NCT06955793
NCT06089122
Lead Sponsor
Prometic Biotherapeutics, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions